SCHEMBL13288637

SCHEMBL13288637

Bc1cnn2c(NCc3cccnc3)cc(C3CCN(C(=O)c4cccs4)CC3)nc12

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 8/20 0.56
▸ KDM4E B2RXH2 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ CHEK1 O14757 1/20 0.44
▸ VNN1 O95497 2/20 0.42
▸ CDK2 P24941 3/20 0.42
▸ CCNE1 P24864 2/20 0.42
▸ ADORA2B P29275 2/20 0.41
▸ MAPT P10636 1/20 0.41
▸ ADORA3 P0DMS8 1/20 0.41
▸ ADORA2A P29274 1/20 0.41
▸ ADORA1 P30542 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13118856 0.91 GSK3B (0.71) GSK3BCDK2CCNE1
SCHEMBL13289048 0.88 GSK3B (0.59) GSK3BALDH1A1CHEK1VNN1CDK2
SCHEMBL13305370 0.87 GSK3B (0.61) GSK3BCHEK1VNN1CDK2CCNE1
SCHEMBL12953848 0.87 GSK3B (0.61) GSK3BCHEK1CDK2CCNE1
SCHEMBL13288814 0.87 GSK3B (0.61) GSK3BCHEK1CDK2CCNE1
SCHEMBL13288837 0.87 GSK3B (0.57) GSK3BKDM4EALDH1A1CHEK1VNN1
SCHEMBL13288839 0.86 GSK3B (0.56) GSK3BCHEK1VNN1CDK2CCNE1
SCHEMBL13289050 0.85 GSK3B (0.58) GSK3BCHEK1CDK2CCNE1
SCHEMBL13288625 0.85 GSK3B (0.56) GSK3BALDH1A1CHEK1VNN1CDK2
SCHEMBL13289043 0.85 GSK3B (0.63) GSK3BCHEK1VNN1CDK2CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
WO-2008130570-A1 NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS SCHERING CORPORATION (US) 2008-10-30 — — WO disclosed
Send feedback